This article is from the source 'guardian' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.

You can find the current article at its original source at http://www.guardian.co.uk/commentisfree/2013/mar/13/in-praise-of-sven-giegold-dangerous-finance

The article has changed 2 times. There is an RSS feed of changes available.

Version 0 Version 1
In praise of… Sven Giegold In praise of… Sven Giegold
(7 months later)
Visitors to www.dangerous-finance.eu are encouraged to vote in a very unusual poll: they can pick Europe's most dangerous financial product. Is it a credit card with punitive rates of interest? Or credit default swaps on the bonds of a developing country? Or perhaps you're most concerned about products that harm the environment – in which case choose between bets on food prices or on the extraction of uranium. Each toxic option comes with its own special reason why it is the most dangerous financial product on the continent. The survey is the brainchild of German MEP Sven Giegold, whose stated aim is to let in more daylight on a notoriously murky and under-regulated sub-industry. But he also raises an important point: we wouldn't let a drugs company launch a new antibiotic without full tests – why should finance be any different? Today is the last day to vote; we are assured that the winner will get no prizes.Visitors to www.dangerous-finance.eu are encouraged to vote in a very unusual poll: they can pick Europe's most dangerous financial product. Is it a credit card with punitive rates of interest? Or credit default swaps on the bonds of a developing country? Or perhaps you're most concerned about products that harm the environment – in which case choose between bets on food prices or on the extraction of uranium. Each toxic option comes with its own special reason why it is the most dangerous financial product on the continent. The survey is the brainchild of German MEP Sven Giegold, whose stated aim is to let in more daylight on a notoriously murky and under-regulated sub-industry. But he also raises an important point: we wouldn't let a drugs company launch a new antibiotic without full tests – why should finance be any different? Today is the last day to vote; we are assured that the winner will get no prizes.
Our editors' picks for the day's top news and commentary delivered to your inbox each morning.